Bectas CEO, Ronan O’Hagan, Will Participate in a panel on “Why Drugs Fail” as part of the SIC Biotech Symposium on Tuesday Janaury 14, 2025.
Bectas Therapeutics to Present at Biotech Showcase 2025
On January 15, 2025 Bectas Therapeutics will present an overview of their precision immunotherapy programs at The Biotech Showcase in San Francisco. This overview will include Bectas’ first-in-class antibody programs that focus on myeloid checkpoints in cancer and autoimmunity and that are enabled by patient selection biomarkers.
Bectas Therapeutics Joins Johnson & Johnson Innovation – JLABS
Bectas Therapeutics became a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS […]
Bectas Therapeutics Awarded $2.75M CPRIT Product Development Seed Grant
Bectas Therapeutics was awarded a $2.75M product development seed grant from the Cancer Prevention Research Institute of Texas (CPRIT). These funds will support the pre-clinical development of Bectas’ first-in-class precision antibody and patient selection biomarker that together are designed to overcome resistance to existing cancer treatments for over 200,000 patients per year. Bectas received the […]
Bectas CEO, Ronan O’Hagan, Featured on BioBytes Podcast
Ronan O’Hagan, CEO and President of Bectas Therapeutics, shares his insights and experiences in the biotech industry. He discusses his career moves and the importance of building teams and organizations. Ronan emphasizes the value of leadership skills and aligning personal and company values. He also provides advice for leaders in biotech and discusses fostering a […]
Bectas CEO, Ronan O’Hagan, Featured on Investor Connect Podcast
On this episode of Investor Connect, Hall T. Martin welcomes Ronan O’Hagan, President & CEO of Bectas Therapeutics Inc., a groundbreaking biotech company focused on revolutionizing precision oncology. Based in Houston, TX, Bectas Therapeutics is committed to developing cancer therapies for people living with cancer who do not benefit from the existing standard-of-care treatments. O’Hagan […]